ARGS Документы SEC - Argos Therapeutics, Inc.- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

CIK

1105533

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Argos Therapeutics, Inc.

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

May 3, 2019	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2019 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission Fi
May 3, 2019	EX-16.1	Letter from PricewaterhouseCoopers LLP to the SEC, dated May 3, 2019, regarding the statements made in this Current Report on Form 8-K Exhibit 16.1 May 3, 2019 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Argos Therapeutics, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Argos Therapeutics, Inc. dated May 1, 2019. We agree with the statements concerning our Fir
February 14, 2019	SC 13D/A	ARGS / Argos Therapeutics, Inc. / ForArgos B.V. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* ARGOS THERAPEUTICS INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 040221 103 (CUSIP Number) ForArgos B.V. Gooimeer 2-35, 1411 DC Naarden The Netherlands (Name, Address and Telephone Number of Person
February 14, 2019	EX-99.2	Shareholders’ Agreement January 27, 2016 ForArgos B.V. by and among Coöperatieve AAC LS U.A. Forbion Co-Investment II Coöperatief U.A. Forbion CF II Co-Invest I Coöperatief U.A. EX-99.2 Exhibit 99.2 Shareholders’ Agreement January 27, 2016 ForArgos B.V. by and among Coöperatieve AAC LS U.A. and Forbion Co-Investment II Coöperatief U.A. and Forbion CF II Co-Invest I Coöperatief U.A. FORARGOS B.V. (“ForArgos”) is a private company with limited liability incorporated under the laws of the Netherlands (besloten vennootschap met beperkte aansprakelijkheid) on January 27, 2016.
February 14, 2019	EX-99.1	Joint Filing Agreement EX-99.1 CUSIP No. 040221 103 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(f) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included a
December 3, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Bankruptcy or Receivership UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 29, 2018 Argos Therapeutics, Inc.
November 19, 2018	EX-10.6	Release of Claims Agreement, dated July 20, 2018, by and between the Registrant and Charles Nicolette Exhibit 10.6 RELEASE OF CLAIMS AGREEMENT In exchange for the consideration set forth in the Retention Agreement dated July 20, 2018 (the “Retention Agreement”) to which this Release of Claims Agreement (the “Release Agreement”) is attached as Exhibit A, including receipt of the Initial Retention Amount (as defined therein) and eligibility to receive the Temporary Revised Salary Amount and Second R
November 19, 2018	EX-10.8	Consulting Agreement, dated August 29, 2018, by and between the Registrant and Richard Katz Exhibit 10.8 ARGOS THERAPEUTICS, INC. CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is entered into as of August 29, 2018 (the “Effective Date”) by and between Argos Therapeutics, Inc. (the “Company”), and Richard Katz (the “Consultant”). WHEREAS, the Consultant has certain knowledge and expertise regarding the Company as a result of having served as its Vice President and Chie
November 19, 2018	EX-10.4	Release of Claims Agreement, dated July 20, 2018, by and between the Registrant and Jeffrey D. Abbey Exhibit 10.4 RELEASE OF CLAIMS AGREEMENT In exchange for the consideration set forth in the Retention Agreement dated July 20, 2018 (the “Retention Agreement”) to which this Release of Claims Agreement (the “Release Agreement”) is attached as Exhibit A, including receipt of the Initial Retention Amount (as defined therein) and eligibility to receive the Temporary Revised Salary Amount and Second R
November 19, 2018	EX-10.5	Release of Claims Agreement, dated July 20, 2018, by and between the Registrant and Richard Katz Exhibit 10.5 RELEASE OF CLAIMS AGREEMENT In exchange for the consideration set forth in the Retention Agreement dated July 20, 2018 (the “Retention Agreement”) to which this Release of Claims Agreement (the “Release Agreement”) is attached as Exhibit A, including receipt of the Initial Retention Amount (as defined therein) and eligibility to receive the Temporary Revised Salary Amount and Second R
November 19, 2018	EX-10.7	Consulting Agreement, dated August 29, 2018, by and between the Registrant and Jeffrey D. Abbey EX-10.7 8 exh107.htm EXHIBIT 10.7 Exhibit 10.7 ARGOS THERAPEUTICS, INC. CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is entered into as of August 29, 2018 (the “Effective Date”) by and between Argos Therapeutics, Inc. (the “Company”), and Jeffrey Abbey (the “Consultant”). WHEREAS, the Consultant has certain knowledge and expertise regarding the Company as a result of having se
November 19, 2018	10-Q	ARGS / Argos Therapeutics, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAPEUTICS, INC. (Exact name of
November 19, 2018	EX-10.9	Consulting Agreement, dated August 29, 2018, by and between the Registrant and Charles Nicolette Exhibit 10.9 ARGOS THERAPEUTICS, INC. CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is entered into as of August 29, 2018 (the “Effective Date”) by and between Argos Therapeutics, Inc. (the “Company”), and Charles Nicolette (the “Consultant”). WHEREAS, the Consultant has certain knowledge and expertise regarding the Company as a result of having served as its Vice President of
November 19, 2018	EX-10.1	Retention Agreement, dated July 20, 2018, by and between the Registrant and Jeffrey D. Abbey EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 RETENTION AGREEMENT This Retention Agreement (the “Agreement”) is entered into as of July 20, 2018, by and between Argos Therapeutics, Inc. (the “Company”) and Jeffrey D. Abbey (“Executive”). WHEREAS, Executive and the Company entered into that certain offer letter dated December 9, 2013 (the “Offer Letter”); and WHEREAS, the Offer Letter provides for
November 19, 2018	EX-10.2	Retention Agreement, dated July 20, 2018, by and between the Registrant and Richard Katz Exhibit 10.2 RETENTION AGREEMENT This Retention Agreement (the “Agreement”) is entered into as of July 20, 2018, by and between Argos Therapeutics, Inc. (the “Company”) and Richard D. Katz (“Executive”). WHEREAS, Executive and the Company entered into that certain offer letter dated July 1, 2016 (the “Offer Letter”); and WHEREAS, the Offer Letter provides for the payment of certain amounts of sala
November 19, 2018	EX-10.3	Retention Agreement, dated July 20, 2018, by and between the Registrant and Charles Nicolette Exhibit 10.3 RETENTION AGREEMENT This Retention Agreement (the “Agreement”) is entered into as of July 20, 2018, by and between Argos Therapeutics, Inc. (the “Company”) and Charles Nicolette (“Executive”). WHEREAS, Executive and the Company entered into that certain offer letter dated December 9, 2013 (the “Offer Letter”); and WHEREAS, the Offer Letter provides for the payment of certain amounts o
November 14, 2018	NT 10-Q	ARGS / Argos Therapeutics, Inc. FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35443 CUSIP NUMBER 040221 202 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2018 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o T
August 20, 2018	10-Q	ARGS / Argos Therapeutics, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 f10q082018p.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAP
August 15, 2018	NT 10-Q	ARGS / Argos Therapeutics, Inc. FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35443 CUSIP NUMBER 040221 202 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2018 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transi
July 20, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 f8k072018.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2018 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction (Commis
May 15, 2018	S-8	ARGS / Argos Therapeutics, Inc. FORM S-8 As filed with the Securities and Exchange Commission on May 15, 2018 Registration No.
May 15, 2018	EX-10.4	Letter from the Registrant to Medinet Co., Ltd., dated February 14, 2018, regarding revocation of certain rights under the novated, amended and restated license agreement Exhibit 10.4 February 14, 2018 BY EMAIL Medinet Co., Ltd. Shin-Yokohama Square Bldg. 14F, 2-3-12 Shin-Yokohama, Kohoku-ku, Yokohama, Kanagawa, 222-0033 JAPAN MEDcell Co., Ltd. 2-8 Tamagawa-dai Setagaya-ku Tokyo, 158-0096 JAPAN Re: Novated, Amended and Restated License Agreement Gentlemen: I am writing on behalf of Argos Therapeutics, Inc. (“Argos”) with respect to the Novated, Amended and Restated
May 15, 2018	10-Q	ARGS / Argos Therapeutics, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 f10q051518p.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERA
May 15, 2018	EX-21.1	Subsidiaries of the Registrant EX-21.1 3 exh211.htm EXHIBIT 21.1 Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction DC Bio Corp. Nova Scotia, Canada Argos Therapeutics (Europe) S.à.r.l Bertrange, Luxembourg
April 24, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 19, 2018 Argos Therapeutics, Inc.
April 19, 2018	EX-99.1	Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives - Company to terminate the ADAPT study – - Company has retained Stifel to provide advice on possible strategic alternatives – - T EXHIBIT 99.1 Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives - Company to terminate the ADAPT study – - Company has retained Stifel to provide advice on possible strategic alternatives – - Trading in the common stock to be transferred from Nasdaq to the OTCQB Venture Market - DURHAM, N.C., April 19, 2018 (GLOBE NEWSWIRE) - Ar
April 19, 2018	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 19, 2018 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission Fil
April 2, 2018	424B5	ARGOS THERAPEUTICS, INC. Up to $6,264,826 Common Stock 424B5 1 f424b5040218.htm 424B5 PROSPECTUS SUPPLEMENT (To Prospectus dated January 24, 2017) Filed Pursuant to Rule 424(b)(5) Registration No. 333-215480 ARGOS THERAPEUTICS, INC. Up to $6,264,826 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated January 24, 2017, filed as a part of our registration statement on Form S-3 (File No. 333-2215480), a
April 2, 2018	EX-10.49	Evaluation and Option Agreement for a Patent License, dated February 1, 2018, by and between the Registrant, Pharmstandard International S.A. and Actigen Limited (filed as Exhibit 10.49 to the Registrant’s Annual Report on Form 10-K on April 2, 2018 and incorporated herein by reference) EX-10.49 3 exh1049.htm EXHIBIT 10.49 Exhibit 10.49 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Evaluation and Option Agreement for a Patent License This Evaluation and Option Agreement for a Patent License ("Agreement"), dated as of February 1, 2018 ("Effective Date"), is by and between Actigen Limited (“Patent
April 2, 2018	10-K	ARGS / Argos Therapeutics, Inc. FORM 10-K (Annual Report) 10-K 1 f10k040218p.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAPEUTI
April 2, 2018	EX-10.51	Third Amendment to License Agreement, dated March 23, 2018, between the Registrant and Lummy (Hong Kong) Co., Ltd. (filed as Exhibit 10.51 to the Registrant’s Annual Report on Form 10-K on April 2, 2018 and incorporated herein by reference) Exhibit 10.51 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Third Amendment to License Agreement between Argos Therapeutics, Inc. (hereinafter “Argos”) - and - Lummy (Hong Kong) Co., Ltd. (hereinafter “China Company”) This Amendment is made as of and effective March 23th, 2018 (“Effective Date”), contingent on th
April 2, 2018	EX-3.1	Restated Certificate of Incorporation of the Registrant, as amended Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF ARGOS THERAPEUTICS, INC. (originally incorporated on May 8, 1997 under the name Dendritix, Inc.) FIRST: The name of the Corporation is Argos Therapeutics, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is 2711 Centerville Road, Suite 400, in the City of Wilmington, County of New Castle, 19808. The name o
April 2, 2018	EX-10.50	Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Exhibit 10.50 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Second Amendment to License Agreement between Argos Therapeutics, Inc. (hereinafter “Argos”) - and - Lummy (Hong Kong) Co., Ltd. (hereinafter “China Company”) This Amendment is made as of and effective 2017-10-18 (“Effective Date”), contingent on the ful
April 2, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 f8k040218.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 2, 2018 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of In
April 2, 2018	EX-99.1	Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights EXHIBIT 99.1 Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights DURHAM, NC, April 02, 2018 (GLOBE NEWSWIRE) - Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported fin
March 7, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 7, 2018 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission File
February 16, 2018	8-K	Other Events 8-K 1 f8k021618.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 15, 2018 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction o
February 14, 2018	EX-99.1	Joint Filing Agreement EX-99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(f) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this
February 14, 2018	SC 13D/A	ARGS / Argos Therapeutics, Inc. / ForArgos B.V. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 )* ARGOS THERAPEUTICS INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 040221 103 (CUSIP Number) ForArgos B.V. Gooimeer 2-35, 1411 DC Naarden The Netherlands (Name, Address and Telephone Number of Perso
February 14, 2018	EX-99.2	Shareholders’ Agreement January 27, 2016 ForArgos B.V. by and among Coöperatieve AAC LS U.A. Forbion Co-Investment II Coöperatief U.A. Forbion CF II Co-Invest I Coöperatief U.A. EX-99.2 3 d719744dex992.htm EX-99.2 Exhibit 99.2 Shareholders’ Agreement January 27, 2016 ForArgos B.V. by and among Coöperatieve AAC LS U.A. and Forbion Co-Investment II Coöperatief U.A. and Forbion CF II Co-Invest I Coöperatief U.A. FORARGOS B.V. (“ForArgos”) is a private company with limited liability incorporated under the laws of the Netherlands (besloten vennootschap met beperkte aansprakeli
February 5, 2018	EX-99.1	Argos Obtains Option to License PD1 Checkpoint Inhibitors - Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call EdgarFiling EXHIBIT 99.1 Argos Obtains Option to License PD1 Checkpoint Inhibitors - Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on Tuesday, February 6, 2018 at 8:30 a.m. ET - DURHAM, N.C., Feb. 05, 2018 (GLOBE NEWSWIRE) - Argos Therapeutics Inc. (NASDAQ
February 5, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 1, 2018 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission F
February 5, 2018	EX-1.1	Amended and Restated Sales Agreement, dated as of February 2, 2018, by and between the Company and Cowen and Company, LLC Exhibit 1.1 ARGOS THERAPEUTICS, INC. Common Stock (par value $0.001 per share) AMENDED AND RESTATED SALES AGREEMENT February 2, 2018 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Reference is made to that certain Sales Agreement, dated May 8, 2015 (the ?Sales Agreement?), by and between Argos Therapeutics, Inc. (the ?Company?) and Cowen and Company, LLC (?Cow
February 2, 2018	424B5	ARGOS THERAPEUTICS, INC. Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-215480 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 24, 2017) ARGOS THERAPEUTICS, INC. $15,000,000 Common Stock On May 8, 2015, we entered into a sales agreement, or the original sales agreement, with Cowen and Company, LLC, or Cowen, pursuant to which we could, from time to time, offer and sell shares of our common stock, $0.001 par v
January 30, 2018	EX-3.1	Certificate of Amendment to Restated Certificate of Incorporation of Argos Therapeutics, Inc. (filed with the Secretary of State of the State of Delaware on January 18, 2018) Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF ARGOS THERAPEUTICS, INC. ARGOS Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), does hereby certify as follows: 1. The current name of the Corporation is Argos Ther
January 30, 2018	8-K/A	Financial Statements and Exhibits 8-K/A 1 f8ka013018.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 18, 2018 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State
January 22, 2018	CORRESP	ARGS / Argos Therapeutics, Inc. ESP CORRESP 1 filename1.htm January 22, 2018 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Argos Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-222414 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Argos Therapeutics, Inc. (the
January 18, 2018	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 17, 2018 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission F
January 8, 2018	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 8, 2018 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission Fi
January 8, 2018	EX-99.1	Argos Announces $1.5 Million Equity Investment by Lummy (Hong Kong), Ltd. EdgarFiling EXHIBIT 99.1 Argos Announces $1.5 Million Equity Investment by Lummy (Hong Kong), Ltd. DURHAM, N.C., Jan. 08, 2018 (GLOBE NEWSWIRE) - Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis? precision immunotherapy technology platform, today announced that it has signed a s
January 4, 2018	S-3	ARGS / Argos Therapeutics, Inc. FORM S-3 S-3 1 fs3010418.htm FORM S-3 As filed with the Securities and Exchange Commission on January 4, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARGOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 56-2110007 (State or other jurisdiction of incorpor
November 28, 2017	EX-10.1	Satisfaction and Release Agreement, dated November 22, 2017, by and between the Company and Saint-Gobain Performance Plastics Corporation, including a form of the Convertible Unsecured Promissory Note to be issued by the Company Exhibit 10.1 SATISFACTION AND RELEASE AGREEMENT This SATISFACTION AND RELEASE AGREEMENT (the ?Agreement?) is dated as of the 22nd day of November, 2017, by and between ARGOS THERAPEUTICS, INC., a Delaware corporation (?Argos?) and SAINT-GOBAIN PERFORMANCE PLASTICS CORPORATION, a California corporation (?SGPPL?). Reference is made to that certain Development Agreement dated as of January 5, 2015, b
November 28, 2017	EX-99.1	Argos Provides Financial Update EdgarFiling EXHIBIT 99.1 Argos Provides Financial Update DURHAM, N.C., Nov. 28, 2017 (GLOBE NEWSWIRE) - Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis? precision immunotherapy technology platform, today announced that TKC Properties, the landlord of the facility in Durham Coun
November 28, 2017	EX-10.2	Registration Rights Agreement, dated November 22, 2017, by and between the Company and Saint-Gobain Performance Plastics Corporation Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of November 22, 2017 by and among Argos Therapeutics, Inc., a Delaware corporation (the ?Company?), and Saint-Gobain Plastics Performance Corporation, a California corporation (?Saint-Gobain?). The parties hereby agree as follows: 1. Certain Definitions. As used in this Agre
November 28, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events 8-K 1 f8k112817.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 22, 2017 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of
November 17, 2017	CORRESP	ARGS / Argos Therapeutics, Inc. ESP November 17, 2017 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 9, 2017	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 f8k110917.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2017 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of I
November 9, 2017	EX-10.4	Form of Restricted Stock Agreement under the 2014 Stock Incentive Plan Exhibit 10.4
November 9, 2017	10-Q	ARGS / Argos Therapeutics, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 f10q110917p.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS T
November 6, 2017	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2017 Argos Therapeutics, Inc.
November 3, 2017	S-3	Argos Therapeutics FORM S-3 As filed with the Securities and Exchange Commission on November 3, 2017 Registration No.
October 27, 2017	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2017 Argos Therapeutics, Inc.
September 28, 2017	EX-24.1	Limited Power Of Attorney For Section 16 Reporting Obligations Exhibit 24.1 Limited Power Of Attorney For Section 16 Reporting Obligations Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Jeffrey D. Abbey, Richard D. Katz and Lori R. Harrelson, signing singly and each acting individually, as the undersigned?s true and lawful attorney-in-fact with full power and authority as hereinafter described to: (1) execute f
September 26, 2017	EX-99.1	Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors DURHAM, N.C., Sept. 26, 2017 (GLOBE NEWSWIRE) - Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform,
September 26, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 26, 2017 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission
September 25, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2017 Argos Therapeutics, Inc.
September 25, 2017	EX-10.1	Satisfaction and Release Agreement, dated September 22, 2017, by and between the Company and Invetech Pty Ltd, including a form of Convertible Unsecured Promissory Note to be issued by the Company (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on September 25, 2017 and incorporated herein by reference) Exhibit 10.1 SATISFACTION AND RELEASE AGREEMENT This SATISFACTION AND RELEASE AGREEMENT (the ?Agreement?) is dated as of the 22nd day of September, 2017, by and between ARGOS THERAPEUTICS, INC., a Delaware corporation (?Argos?) and INVETECH PTY LTD, an Australian company (?Invetech?). Reference is made to that certain Development Agreement with an effective date of October 7, 2013, by and between
September 25, 2017	EX-10.2	Registration Rights Agreement, dated September 22, 2017, by and between the Company and Invetech Pty Ltd Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of September 22, 2017 by and among Argos Therapeutics, Inc., a Delaware corporation (the ?Company?), and Invetech Pty Ltd (?Invetech?). The parties hereby agree as follows: 1. Certain Definitions. As used in this Agreement, the following terms shall have the following meanin
September 12, 2017	8-K	Financial Statements and Exhibits, Other Events 8-K 1 f8k091217.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 12, 2017 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction
September 12, 2017	EX-99.1	Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress EX-99.1 2 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress DURHAM, N.C., Sept. 12, 2017 (GLOBE NEWSWIRE) - Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technolo
September 5, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 f8k090517.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 30, 2017 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of
August 30, 2017	S-8	Argos Therapeutics FORM S-8 As filed with the Securities and Exchange Commission on August 30, 2017 Registration No.
August 24, 2017	CORRESP	ARGS / Argos Therapeutics, Inc. ESP CORRESP 1 filename1.htm August 24, 2017 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Argos Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-220001 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Argos Therapeutics, Inc. (the “
August 16, 2017	S-3	Argos Therapeutics FORM S-3 As filed with the Securities and Exchange Commission on August 16, 2017 Registration No.
August 9, 2017	10-Q	ARGS / Argos Therapeutics, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAPEUTICS, INC. (Exact name of regis
August 2, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2017 ARGOS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission File
August 2, 2017	EX-10.1	2014 Stock Incentive Plan, as amended Exhibit 10.1 ARGOS THERAPEUTICS, INC. 2014 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2014 Stock Incentive Plan (the ?Plan?) of Argos Therapeutics, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the Company
July 6, 2017	DEF 14A	Argos Therapeutics FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of
June 26, 2017	SC 13D/A	ARGS / Argos Therapeutics, Inc. / Pharmstandard International S.A. - SCHEDULE 13DA BY PHARMSTANDARD INTERNATIONAL S.A. FOR ARGOS THERAPEUTICS, INC. Activist Investment SC 13D/A 1 s13da062217-argostherap.htm SCHEDULE 13DA BY PHARMSTANDARD INTERNATIONAL S.A. FOR ARGOS THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* ARGOS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 040221 103 (CUSIP Numb
June 23, 2017	PRE 14A	Argos Therapeutics PRE 14A PRE 14A 1 pre14a062317.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy S
June 16, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events 8-K 1 f8k061617.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2017 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Inco
June 16, 2017	EX-10.1	NOTE PURCHASE AGREEMENT Exhibit 10.1 NOTE PURCHASE AGREEMENT This NOTE PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of June 15, 2017 by and among Argos Therapeutics, Inc., a Delaware corporation (the ?Company?) and Pharmstandard International S.A. (the ?Investor?). Recitals A. The Investor wishes to purchase from the Company, and the Company wishes to sell and issue to the Investor, upon the terms an
June 16, 2017	EX-10.2	REGISTRATION RIGHTS AGREEMENT Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of June 15, 2017 by and among Argos Therapeutics, Inc., a Delaware corporation (the ?Company?), and Pharmstandard International S.A. (?PHS?). Capitalized terms used herein have the respective meanings ascribed thereto in that certain Note Purchase Agreement dated as of the d
June 16, 2017	EX-99.1	Argos Therapeutics Announces $6,000,000 Secured Convertible Note Financing EdgarFiling EXHIBIT 99.1 Argos Therapeutics Announces $6,000,000 Secured Convertible Note Financing DURHAM, N.C., June 16, 2017 (GLOBE NEWSWIRE) - Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis? technology platform, today an
May 10, 2017	EX-10.7	Lease Termination Agreement, dated March 31, 2017, by and between Registrant and Keystone-Centennial II, LLC Exhibit 10.7 LEASE TERMINATION AGREEMENT THIS LEASE TERMINATION AGREEMENT (this "Agreement") is entered into effective March 31, 2017, by and between Keystone-Centennial II, LLC, a North Carolina limited liability company, ("Landlord"), and Argos Therapeutics, Inc., a Delaware corporation, ("Tenant"). RECITALS Pursuant to that Lease Agreement dated January 17, 2017, entered into by Tenant and Land
May 10, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAPEUTICS, INC. (Exact name of regi
May 10, 2017	EX-10.6	First Amendment to License Agreement, dated December 5, 2016, by and between Registrant and Lummy (Hong Kong) Co., Ltd. Confidential Materials omitted and filed separately with the Securities and Exchange Commission.
May 4, 2017	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2017 Argos Therapeutics, Inc.
May 1, 2017	10-K/A	Argos Therapeutics FORM 10-K/A (Annual Report) 10-K/A 1 f10ka050117.htm FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss
April 18, 2017	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2017 Argos Therapeutics, Inc.
April 18, 2017	EX-99.1	Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial EdgarFiling EXHIBIT 99.1 Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial DURHAM, N.C., April 18, 2017 (GLOBE NEWSWIRE) - Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis? precision immunotherapy technology platform, tod
April 18, 2017	EX-99.2	Webcast April 18, 2017 Results of February Interim Analysis of ADAPT Trial and Perspective on Decision to Keep Trial Open Any statements in this presentation about Argos' future expectations, plans and prospects, including statements about the ADAPT EXHIBIT 99.2 Webcast April 18, 2017 Results of February Interim Analysis of ADAPT Trial and Perspective on Decision to Keep Trial Open Any statements in this presentation about Argos' future expectations, plans and prospects, including statements about the ADAPT trial and the interim data from the trial, Argos' anticipated meeting with the FDA, clinical development of Argos' product candidates and
April 13, 2017	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 13, 2017 Argos Therapeutics, Inc.
April 4, 2017	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2017 Argos Therapeutics, Inc.
March 28, 2017	S-8	Argos Therapeutics FORM S-8 S-8 1 s8032717.htm FORM S-8 As filed with the Securities and Exchange Commission on March 28, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARGOS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2110007 (State or Other Jurisdiction of Incorporat
March 23, 2017	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 17, 2017 Argos Therapeutics, Inc.
March 16, 2017	EX-4.3	EX-4.3 Exhibit 4.3
March 16, 2017	EX-10.44	Confidential Materials omitted and filed separately with the Securities and Exchange Commission .Double asterisks denote omissions. Exhibit 10.44 Confidential Materials omitted and filed separately with the Securities and Exchange Commission .Double asterisks denote omissions. OMB Approval 2700-0042 1. CONTRACT ID CODE PAGE OF PAGES AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1 6 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable) Thirteen (13) See Block 16C. N
March 16, 2017	EX-10.40	LEASE TERM SHEET Exhibit 10.40 LEASE TERM SHEET THIS LEASE TERM SHEET is made a part of the attached Lease Agreement between Landlord and Tenant. Use of the following capitalized terms (indicated in bold type) in this Lease shall be deemed a reference to the information set out below. • Landlord: Keystone-Centennial II, LLC a North Carolina limited liability company 5410 Trinity Road, Suite 215 Raleigh, NC 27607 A
March 16, 2017	EX-10.28	Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SECOND AMENDMENT Exhibit 10.28 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SECOND AMENDMENT THIS SECOND AMENDMENT TO DEVELOPMENT AGREEMENT (the ?Second Amendment?) is entered into by and between SAINT-GOBAIN PERFORMANCE PLASTICS CORPORATION, a California corporation having an office at 31500 Solon Road, Solon, OH 44139 (?SGPPL?
March 16, 2017	EX-4.5	AMENDMENT NO. 3 TO FIFTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT Exhibit 4.5 AMENDMENT NO. 3 TO FIFTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amendment No. 3 (this ?Amendment?) to the Fifth Amended and Restated Registration Rights Agreement, dated August 9, 2013 (the ?Registration Rights Agreement?), by and among the Company and the Holders (as defined therein) is entered into as of the 6th day of March, 2017 by and among Argos Therapeutics, Inc
March 16, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAPEUTICS, INC. (Exact name of registran
March 9, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2017 Argos Therapeutics, Inc.
March 6, 2017	EX-10.1	March 2, 2017 EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 March 2, 2017 VIA ELECTRONIC AND REGULAR MAIL Argos Therapeutics, Inc. 4233 Technology Drive Durham, NC 27704 Attn: Vice President of Finance Re: Venture Loan and Security Agreement dated as of September 29, 2014 (as amended from time to time, the “Loan Agreement”) by and among Argos Therapeutics, Inc. (“Borrower”), Horizon Credit II LLC (“HCII”), as
March 6, 2017	EX-10.2	ARGOS THERAPEUTICS, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK Exhibit 10.2 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT
March 6, 2017	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2017 Argos Therapeutics, Inc.
March 6, 2017	EX-10.3	ARGOS THERAPEUTICS, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK Exhibit 10.3 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT
March 6, 2017	EX-10.4	ARGOS THERAPEUTICS, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK Exhibit 10.4 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT
March 2, 2017	EX-99.2	Shareholders’ Agreement January 27, 2016 ForArgos B.V. by and among Coöperatieve AAC LS U.A. Forbion Co-Investment II Coöperatief U.A. Forbion CF II Co-Invest I Coöperatief U.A. EX-99.2 Exhibit 99.2 Shareholders’ Agreement January 27, 2016 ForArgos B.V. by and among Coöperatieve AAC LS U.A. and Forbion Co-Investment II Coöperatief U.A. and Forbion CF II Co-Invest I Coöperatief U.A. FORARGOS B.V. (“ForArgos”) is a private company with limited liability incorporated under the laws of the Netherlands (besloten vennootschap met beperkte aansprakelijkheid) on January 27, 2016.
March 2, 2017	EX-99.1	Joint Filing Agreement EX-99.1 CUSIP No. 040221 103 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(f) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included a
March 2, 2017	SC 13D	ARGS / Argos Therapeutics, Inc. / ForArgos B.V. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* ARGOS THERAPEUTICS INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 040221 103 (CUSIP Number) ForArgos B.V. Gooimeer 2-35, 1411 DC Naarden The Netherlands (Name, Address and Telephone Number of Person Au
February 22, 2017	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 22, 2017 Argos Therapeutics, Inc.
February 13, 2017	SC 13G/A	ARGS / Argos Therapeutics, Inc. / INTERSOUTH PARTNERS IV LP /NC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 Argos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 040221103 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
January 23, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 17, 2017 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission F
January 23, 2017	EX-99.1	Argos Therapeutics Completes Lease Agreement for Commercial Manufacturing Space on the Centennial Campus of North Carolina State University 40,000 square feet of newly constructed space at the Center for Technology & Innovation to support initial com EdgarFiling
January 20, 2017	CORRESP	Argos Therapeutics ESP January 20, 2017 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
January 9, 2017	EX-4.6	Form of Subordinated Note (FACE OF SECURITY) Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE
January 9, 2017	S-3	As filed with the Securities and Exchange Commission on January 9, 2017 As filed with the Securities and Exchange Commission on January 9, 2017 Registration No.
January 9, 2017	EX-4.5	Form of Senior Note (FACE OF SECURITY) Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE
January 9, 2017	EX-12.1	RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS Exhibit 12.1 RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS The following table sets forth our ratio of earnings to fixed charges and ratios of earnings to combined fixed charges and preferred stock dividends for each of the periods indicated. Fixed charges include interest expense on debt, amortization of discount and the portion
January 9, 2017	EX-4.4	ARGOS THERAPEUTICS, INC. Dated as of _______________ SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) EX-4.4 3 exh44.htm EXHIBIT 4.4 Exhibit 4.4 ARGOS THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4
January 9, 2017	EX-4.3	ARGOS THERAPEUTICS, INC. Dated as of _______________ SENIOR DEBT SECURITIES Exhibit 4.3 ARGOS THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES i CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b)
December 15, 2016	EX-99.1	Argos Therapeutics Appoints Dr. Ralph Snyderman and Irackly Mtibelishvily to the Company’s Board of Directors - Dr. Snyderman widely considered the ‘Father of Personalized Medicine’ - EdgarFiling
December 15, 2016	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 9, 2016 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission F
November 14, 2016	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 14, 2016 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission
November 14, 2016	EX-99.1	Argos Therapeutics Reports Third Quarter 2016 Financial Results and Recent Operational Highlights - Dr. Richard D. Katz Joined as Chief Financial Officer - - Raised Gross Proceeds of $50 million in Follow-on Offering - - First Patient Dosed in Stage EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Argos Therapeutics Reports Third Quarter 2016 Financial Results and Recent Operational Highlights - Dr. Richard D. Katz Joined as Chief Financial Officer - - Raised Gross Proceeds of $50 million in Follow-on Offering - - First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in HIV - - Investor Day Scheduled for December 7, 2016 - - Thi
November 14, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAPEUTICS, INC. (Exact name of
November 14, 2016	EX-10.4	SIXTH AMENDMENT TO LEASE AGREEMENT AND FIFTH AMENDMENT TO PURCHASE AND SALE AGREEMENT Exhibit 10.4 SIXTH AMENDMENT TO LEASE AGREEMENT AND FIFTH AMENDMENT TO PURCHASE AND SALE AGREEMENT THIS SIXTH AMENDMENT TO LEASE AGREEMENT AND FIFTH AMENDMENT TO PURCHASE AND SALE AGREEMENT (this ?Agreement?), is dated effective as of September 30, 2016 (the ?Effective Date?), by and between TKC LXXII, LLC, a North Carolina limited liability company (?TKC?), and ARGOS THERAPEUTICS, INC., a Delawar
October 18, 2016	SC 13D/A	Argos Therapeutics SCHEDULE 13D/A - AMENDMENT NO. 4 FOR ARGOS THERAPEUTICS, INC. BY PHARMSTANDARD INTERNATIONAL S.A. (Activist Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* ARGOS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 040221 103 (CUSIP Number) Pharmstandard International S.A 10a, rue Henri Schnadt Luxembourg, N4 L-2530 +352 24840131 (Name, Address and Tele
August 18, 2016	SC 13D/A	ARGS / Argos Therapeutics, Inc. / Pharmstandard International S.A. - SCHEDULE 13D/A FOR ARGOS THERAPEUTICS, INC. BY PHARMSTANDARD INTERNATIONAL S.A. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ARGOS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 040221 103 (CUSIP Number) Pharmstandard International S.A 10a, rue Henri Schnadt Luxembourg, N4 L-2530 +352 24840131 (Name, Address and Tele
August 18, 2016	SC 13D/A	ARGS / Argos Therapeutics, Inc. / Pharmstandard International S.A. - SCHEDULE 13D/A FOR ARGOS THERAPEUTICS, INC. BY PHARMSTANDARD INTERNATIONAL S.A. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ARGOS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 040221 103 (CUSIP Number) Pharmstandard International S.A 10a, rue Henri Schnadt Luxembourg, N4 L-2530 +352 24840131 (Name, Address and Tele
August 15, 2016	S-8	Argos Therapeutics FORM S-8 S-8 1 fs8081516.htm FORM S-8 As filed with the Securities and Exchange Commission on August 15, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2110007 (State or Other Jurisdiction of Incorpor
August 15, 2016	EX-99.1	ARGOS THERAPEUTICS, INC. Nonstatutory Stock Option Agreement Exhibit 99.1 ARGOS THERAPEUTICS, INC. Nonstatutory Stock Option Agreement 1. Grant of Option. This agreement evidences the grant by Argos Therapeutics, Inc., a Delaware corporation (the ?Company?), on July 11, 2016 (the ?Grant Date?) to Richard Katz, an employee of the Company (the ?Participant?), of an option to purchase, in whole or in part, on the terms provided herein, a total of 300,000 share
August 15, 2016	EX-99.1	ARGOS THERAPEUTICS, INC. Nonstatutory Stock Option Agreement Exhibit 99.1 ARGOS THERAPEUTICS, INC. Nonstatutory Stock Option Agreement 1. Grant of Option. This agreement evidences the grant by Argos Therapeutics, Inc., a Delaware corporation (the ?Company?), on July 11, 2016 (the ?Grant Date?) to Richard Katz, an employee of the Company (the ?Participant?), of an option to purchase, in whole or in part, on the terms provided herein, a total of 300,000 share
August 15, 2016	S-8	Argos Therapeutics FORM S-8 S-8 1 fs8081516.htm FORM S-8 As filed with the Securities and Exchange Commission on August 15, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2110007 (State or Other Jurisdiction of Incorpor
August 15, 2016	EX-10.1	ARGOS THERAPEUTICS, INC. 4233 TECHNOLOGY DRIVE DURHAM, NC 27704 Exhibit 10.1 ARGOS THERAPEUTICS, INC. 4233 TECHNOLOGY DRIVE DURHAM, NC 27704 June 10, 2016 VIA email Joan C. Winterbottom 6986 Phillips Mill Road New Hope, PA 18938 Re: Amended and Restated Offer Letter Dear Joan: This letter agreement (the “Agreement”) shall serve to amend and restate the terms and conditions of the employment offer letter dated February 3, 2015 (the “Offer Letter”) between you a
August 15, 2016	EX-10.3	FIFTH AMENDMENT TO LEASE AGREEMENT AND THIRD AMENDMENT TO PURCHASE AND SALE AGREEMENT Exhibit 10.3 EXECUTION COPY FIFTH AMENDMENT TO LEASE AGREEMENT AND THIRD AMENDMENT TO PURCHASE AND SALE AGREEMENT THIS FIFTH AMENDMENT TO LEASE AGREEMENT AND THIRD AMENDMENT TO PURCHASE AND SALE AGREEMENT (this “Omnibus Amendment”), dated effective as of July 1, 2016, by and between TKC LXXII, LLC, a North Carolina limited liability company (“TKC”), and ARGOS THERAPEUTICS, INC., a Delaware corpora
August 15, 2016	EX-10.1	ARGOS THERAPEUTICS, INC. 4233 TECHNOLOGY DRIVE DURHAM, NC 27704 Exhibit 10.1 ARGOS THERAPEUTICS, INC. 4233 TECHNOLOGY DRIVE DURHAM, NC 27704 June 10, 2016 VIA email Joan C. Winterbottom 6986 Phillips Mill Road New Hope, PA 18938 Re: Amended and Restated Offer Letter Dear Joan: This letter agreement (the “Agreement”) shall serve to amend and restate the terms and conditions of the employment offer letter dated February 3, 2015 (the “Offer Letter”) between you a
August 15, 2016	EX-4.2	AMENDMENT NO. 2 TO FIFTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT Exhibit 4.2 AMENDMENT NO. 2 TO FIFTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amendment No. 2 (this “Amendment”) to the Fifth Amended and Restated Registration Rights Agreement, dated August 9, 2013 (the “Registration Rights Agreement”), by and among the Company and the Holders (as defined therein) is entered into as of the 14th day of July, 2016 by and among Argos Therapeutics, Inc
August 15, 2016	EX-4.2	AMENDMENT NO. 2 TO FIFTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT Exhibit 4.2 AMENDMENT NO. 2 TO FIFTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amendment No. 2 (this “Amendment”) to the Fifth Amended and Restated Registration Rights Agreement, dated August 9, 2013 (the “Registration Rights Agreement”), by and among the Company and the Holders (as defined therein) is entered into as of the 14th day of July, 2016 by and among Argos Therapeutics, Inc
August 15, 2016	EX-10.3	FIFTH AMENDMENT TO LEASE AGREEMENT AND THIRD AMENDMENT TO PURCHASE AND SALE AGREEMENT Exhibit 10.3 EXECUTION COPY FIFTH AMENDMENT TO LEASE AGREEMENT AND THIRD AMENDMENT TO PURCHASE AND SALE AGREEMENT THIS FIFTH AMENDMENT TO LEASE AGREEMENT AND THIRD AMENDMENT TO PURCHASE AND SALE AGREEMENT (this “Omnibus Amendment”), dated effective as of July 1, 2016, by and between TKC LXXII, LLC, a North Carolina limited liability company (“TKC”), and ARGOS THERAPEUTICS, INC., a Delaware corpora
August 15, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAPEUTICS, INC. (Exact name of regis
August 12, 2016	CORRESP	Argos Therapeutics ESP SEC Letter August 12, 2016 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
August 12, 2016	CORRESP	Argos Therapeutics ESP SEC Letter August 12, 2016 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
August 10, 2016	EX-99.1	Argos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational Highlights - Independent Data Monitoring Committee Recommended Continuation of Phase 3 ADAPT Trial of AGS-003 in Metastatic Renal Cell Carcinoma - - Closed on $29 EdgarFiling EXHIBIT 99.1 Argos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational Highlights - Independent Data Monitoring Committee Recommended Continuation of Phase 3 ADAPT Trial of AGS-003 in Metastatic Renal Cell Carcinoma - - Closed on $29.8 million Second Tranche of March 2016 Financing - - Raised Gross Proceeds of $50.0 million in Follow-on Offering - - Entere
August 10, 2016	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 10, 2016 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission Fi
July 29, 2016	EX-99.1	Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and Warrants EX-99.1 Exhibit 99.1 Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and Warrants DURHAM, N.C., July 28, 2016 ? Argos Therapeutics, Inc. (Nasdaq: ARGS) (?Argos?), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis? technology platform, today announced the
July 29, 2016	EX-4.1	WARRANT AGREEMENT EX-4.1 Exhibit 4.1 WARRANT AGREEMENT WARRANT AGREEMENT, dated as of , 2016 (the ?Agreement?), by and among Argos Therapeutics, Inc., a Delaware corporation (the ?Company?), Computershare Inc., a Delaware corporation (?Computershare?), and its wholly-owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company (the ?Trust Company? and collectively with Computershare, ?Wa
July 29, 2016	EX-1.1	9,090,909 Shares of Common Stock Warrants to Purchase 6,818,181 Shares of Common Stock Argos Therapeutics, Inc. UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 9,090,909 Shares of Common Stock and Warrants to Purchase 6,818,181 Shares of Common Stock Argos Therapeutics, Inc. UNDERWRITING AGREEMENT July 28, 2016 STIFEL, NICOLAUS & COMPANY, INCORPORATED JMP Securities LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Stifel, Nicolaus & Company, Incorporated 787 7th Avenue, 11th Floor New York, New York 100
July 29, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2016 ARGOS THERAPEUTICS, INC.
July 29, 2016	424B5	9,090,909 Shares of Common Stock Warrants to Purchase up to 6,818,181 Shares of Common Stock $5.50 per share and accompanying warrant Prospectus Supplement Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No.
July 28, 2016	FWP	ARGOS THERAPEUTICS, INC. 9,090,909 Shares of Common Stock and Warrants to Purchase 6,818,181 Shares of Common Stock FWP Filed Pursuant to Rule 433 of the Securities Act of 1933, as amended Issuer Free Writing Prospectus dated July 28, 2016 Relating to Preliminary Prospectus dated July 27, 2016 Registration No.
July 27, 2016	424B5	SUBJECT TO COMPLETION, DATED JULY 27, 2016 Preliminary Prospectus Supplement Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No.
July 27, 2016	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 27, 2016 ARGOS THERAPEUTICS, INC.
July 22, 2016	S-3	Argos Therapeutics FORM S-3 As filed with the Securities and Exchange Commission on July 22, 2016 Registration No.
July 12, 2016	SC 13D/A	ARGS / Argos Therapeutics, Inc. / Pharmstandard International S.A. - SCHEDULE 13D - AMENDMENT NO. 2 FOR ARGOS THERAPEUTICS, INC. BY PHARMSTANDARD INTERNATIONAL S.A. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARGOS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 040221 103 (CUSIP Number) Pharmstandard International S.A. 10a, rue Henri Schnadt Luxembourg, N4 L-2530 +352 24840131 (Name, Address and Tel
July 11, 2016	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2016 Argos Therapeutics, Inc.
July 11, 2016	EX-10.1	ARGOS THERAPEUTICS, INC. 4233 TECHNOLOGY DRIVE DURHAM, NC 27704 EX-10.1 2 exh101.htm EXHIBIT 10.1 Exhibit 10.1 ARGOS THERAPEUTICS, INC. 4233 TECHNOLOGY DRIVE DURHAM, NC 27704 July 1, 2016 VIA email Richard D. Katz 209 Sierra Drive Chapel Hill, NC 27514 Dear Rich: I am pleased to extend to you this offer of employment with Argos Therapeutics, Inc. (“Argos Therapeutics”) by way of this offer letter (the “Offer Letter”). We at Argos Therapeutics are excited about
July 11, 2016	EX-99.1	Dr. Richard D. Katz Joins Argos Therapeutics as Chief Financial Officer EdgarFiling EXHIBIT 99.1 Dr. Richard D. Katz Joins Argos Therapeutics as Chief Financial Officer DURHAM, N.C., July 11, 2016 (GLOBE NEWSWIRE) - Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today
June 29, 2016	8-K	Other Events 8-K 1 f8k062816.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2016 ARGOS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of In
June 13, 2016	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2016 ARGOS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission File
May 27, 2016	SC 13D/A	ARGS / Argos Therapeutics, Inc. / Pharmstandard International S.A. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARGOS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 040221 103 (CUSIP Number) Pharmstandard International S.A 10a, rue Henri Schnadt Luxembourg, L-2530 +352 24840131 (Name, Address
May 27, 2016	EX-2	SALE AND PURCHASE AGREEMENT EX-2 Exhibit 2 SALE AND PURCHASE AGREEMENT This SALE AND PURCHASE AGREEMENT (this “Agreement”), dated as of May 19, 2016 (the “Effective Date”), by and between Pharmstandard International S.
May 25, 2016	CORRESP	Argos Therapeutics ESP May 25, 2016 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 16, 2016	S-8	Argos Therapeutics FORM S-8 S-8 1 s8051616.htm FORM S-8 As filed with the Securities and Exchange Commission on May 16, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2110007 (State or Other Jurisdiction of Incorporatio
May 16, 2016	EX-99.1	ARGOS THERAPEUTICS, INC. Nonstatutory Stock Option Agreement Exhibit 99.1 ARGOS THERAPEUTICS, INC. Nonstatutory Stock Option Agreement 1. Grant of Option. This agreement evidences the grant by Argos Therapeutics, Inc., a Delaware corporation (the ?Company?), on January 19, 2016 (the ?Grant Date?) to Lee Allen, an employee of the Company (the ?Participant?), of an option to purchase, in whole or in part, on the terms provided herein, a total of 300,000 share
May 16, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAPEUTICS, INC. (Exact name of regi
May 16, 2016	EX-10.1	ARGOS THERAPEUTICS, INC. 4233 TECHNOLOGY DRIVE DURHAM, NC 27704 Exhibit 10.1 ARGOS THERAPEUTICS, INC. 4233 TECHNOLOGY DRIVE DURHAM, NC 27704 December 2, 2015 VIA email Lee F. Allen 3 Paniolo Road Ladera Ranch, CA 92656 Dear Lee: I am pleased to extend to you this offer of employment with Argos Therapeutics, Inc. (“Argos Therapeutics”) by way of this offer letter (the “Offer Letter”). We at Argos Therapeutics are excited about the challenges and opportunities t
May 13, 2016	S-3	Argos Therapeutics S-3 As filed with the Securities and Exchange Commission on May 13, 2016 Registration No.
May 12, 2016	EX-99.1	Argos Therapeutics Reports First Quarter 2016 Financial Results and Operational Highlights - Entered into Equity Financing for Up to $60 million - - Phase 3 ADAPT trial of AGS-003 in Metastatic Renal Cell Carcinoma On Track for Upcoming Review by Ind EdgarFiling EXHIBIT 99.1 Argos Therapeutics Reports First Quarter 2016 Financial Results and Operational Highlights - Entered into Equity Financing for Up to $60 million - - Phase 3 ADAPT trial of AGS-003 in Metastatic Renal Cell Carcinoma On Track for Upcoming Review by Independent Data Monitoring Committee - - Dr. Lee F. Allen joined as Chief Medical Officer - - Investigator-initiated Phase 2 St
May 12, 2016	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 12, 2016 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission File
April 29, 2016	DEFA14A	Argos Therapeutics DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of
April 29, 2016	DEF 14A	Argos Therapeutics DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of
April 19, 2016	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 15, 2016 Argos Therapeutics, Inc.
April 15, 2016	PRE 14A	Argos Therapeutics PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of
April 4, 2016	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2016 ARGOS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporatio
April 4, 2016	EX-99.2	Partial Transcript of Conference Call held on March 29, 2016 Exhibit 99.2 Partial Transcript of Conference Call held on March 29, 2016 Lori Harrelson - Argos Therapeutics, Inc. - VP, Finance Thank you, Charles. Our cash, cash equivalents and short-term investments as of December 31, 2015 totaled $7.2 million compared to $56.2 million as of December 31, 2014. The decrease results primarily from cash used to fund our Phase 3 ADAPT clinical trial and our comme
March 31, 2016	S-8	Argos Therapeutics FORM S-8 As filed with the Securities and Exchange Commission on March 31, 2016 Registration No.
March 30, 2016	EX-10.31	ARGOS THERAPEUTICS, INC. 4233 TECHNOLOGY DRIVE DURHAM, NC 27704 Exhibit 10.31 ARGOS THERAPEUTICS, INC. 4233 TECHNOLOGY DRIVE DURHAM, NC 27704 January 30, 2015 VIA email Joan Winterbottom 6986 Phillips Mill Road New Hope, PA 18938 Dear Joan: I am pleased to extend to you this offer of employment with Argos Therapeutics, Inc. (?Argos Therapeutics?) by way of this offer letter (the ?Offer Letter?). We at Argos Therapeutics are excited about the challenges and opp
March 30, 2016	EX-10.30	Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Exhibit 10.30 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. MASTER PROCESS DEVELOPMENT AND SUPPLY AGREEMENT This Master Process Development and Supply Agreement (?Agreement?) by and between CELLSCRIPT, LLC (?CELLSCRIPT?), a Wisconsin limited liability company located at 726 Post Road, Madison, Wisconsin 53713, an
March 30, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAPEUTICS, INC. (Exact name of registran
March 29, 2016	EX-99.1	Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights - Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 in July 2015 – - Independent Data Monitoring Committee (IDMC) EdgarFiling EXHIBIT 99.1 Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights - Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 in July 2015 ? - Independent Data Monitoring Committee (IDMC) Recommended Continuation of Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 Following Data Reviews in June and December 2015
March 29, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 f8k032916.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2016 ARGOS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of I
March 22, 2016	SC 13D	ARGS / Argos Therapeutics, Inc. / Pharmstandard International S.A. - SCHEDULE 13D BY ARGOS THERAPEUTICS, INC. BY PHARMSTANDARD INTERNATIONAL S.A. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ARGOS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 040221 103 (CUSIP Number) Pharmstandard International S.A 10a, rue Henri Schnadt Luxembourg, N4 L-2530 +352 24840131 (Name, Address and Telep
March 7, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2016 ARGOS THERAPEUTICS, INC.
March 7, 2016	EX-10.3	REGISTRATION RIGHTS AGREEMENT EX-10.3 Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of March 4, 2016 by and among Argos Therapeutics, Inc., a Delaware corporation (the ?Company?), and the ?Investors? named in that certain Securities Purchase Agreement by and among the Company and the Investors (the ?Purchase Agreement?). Capitalized terms used herei
March 7, 2016	EX-10.2	Void after 5:00 p.m. (New York time) on the [●] day of March, 2021. Number of Warrant Shares: Warrant No. EX-10.2 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV
March 7, 2016	EX-10.1	SECURITIES PURCHASE AGREEMENT EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of March 4, 2016 by and among Argos Therapeutics, Inc., a Delaware corporation (the ?Company?), and the Investors identified on Exhibit A attached hereto (each an ?Investor? and collectively the ?Investors?). RECITALS A. The Investors wish to purchase from the Compan
March 7, 2016	EX-99.1	Argos Therapeutics Announces Financing of up to $60 Million EX-99.1 5 d129578dex991.htm EX-99.1 Exhibit 99.1 Argos Therapeutics Announces Financing of up to $60 Million DURHAM, N.C., March 7, 2016 – Argos Therapeutics, Inc. (Nasdaq: ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that it
February 17, 2016	SC 13G	ARGS / Argos Therapeutics, Inc. / Forbion Co-Investment II Cooperatief U.A. - SC 13G Passive Investment SC 13G 1 d143634dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARGOS THERAPEUTICS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 040221 103 (CUSIP Number) 31 DECEMBER 2015 (Date of Event Which Requires Filing of this Statement) Check the
February 17, 2016	SC 13G	ARGS / Argos Therapeutics, Inc. / Cooperatieve AAC LS U.A. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARGOS THERAPEUTICS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 040221 103 (CUSIP Number) 31 DECEMBER 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa
February 17, 2016	EX-99.1	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 Exhibit 99.1 CUSIP No. 040221 103 13G Page 8 of 8 Pages JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addit
February 17, 2016	EX-99.1	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 CUSIP No. 040221 103 13G Page 8 of 8 Pages Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addit
February 16, 2016	SC 13G	ARGS / Argos Therapeutics, Inc. / TVM V LIFE SCIENCE VENTURES GMBH & CO KG - ARGOS THERAPEUTICS, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. ) Argos Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 040221103 (CUSIP Number) December 31, 2015 (Date of Event which Requires
January 14, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2016 Argos Therapeutics, Inc.
December 29, 2015	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 22, 2015 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (Commission
November 16, 2015	EX-99	Argos Therapeutics Reports Third Quarter 2015 Financial Results and Operational Highlights Argos Therapeutics Reports Third Quarter 2015 Financial Results and Operational Highlights EXHIBIT 99.
November 16, 2015	EX-10.1	SOC 25.55 Exhibit 10.1 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. OMB Approval 2700-0042 1. CONTRACT ID CODE PAGE OF PAGES AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1 12 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable) Eleven (11) See Block 16C. 350
November 16, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2015 Argos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35443 56-2110007 (State or other jurisdiction of incorpo
November 16, 2015	S-8	Argos Therapeutics FORM S-8 As filed with the Securities and Exchange Commission on November 16, 2015 Registration No.
November 16, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAPEUTICS, INC. (Exact name of
September 23, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits Form 8-K Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2015 Argos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35443 56-2110007 (State or other jurisdiction of incorp
September 23, 2015	EX-99	Robert F. Carey Appointed to the Board of Directors of Argos Therapeutics Robert F. Carey Appointed to the Board of Directors of Argos Therapeutics EXHIBIT 99.1 Robert F. Carey Appointed to the Board of Directors of Argos Therapeutics DURHAM, N.C., Sept. 23, 2015 (GLOBE NEWSWIRE) - Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis? tech
August 14, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________ 10-Q 1 gff10q081415.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERA
August 12, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 document.htm FORM 8-K FILING DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2015 Argos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35443 56-2110007 (State or oth
August 12, 2015	EX-99	Argos Therapeutics Reports Second Quarter 2015 Financial Results and Operational Highlights Argos Therapeutics Reports Second Quarter 2015 Financial Results and Operational Highlights EXHIBIT 99.
June 22, 2015	8-K	Argos Therapeutics FORM 8-K (Current Report/Significant Event) f8k062215.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2015 ARGOS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Incorporation) (C
May 18, 2015	DEF 14A	Argos Therapeutics DEFINITIVE PROXY STATEMENT def14a051815.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide
May 15, 2015	EX-10.2	Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Exhibit 10.2 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Execution Copy LICENSE AGREEMENT by and between ARGOS THERAPEUTICS, INC. and LUMMY (HONG KONG) CO., LTD LICENSE AGREEMENT THIS LICENSE AGREEMENT (the ?Agreement?), effective as of the Effective Date (hereinafter defined), is by and between Argos Therapeut
May 15, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 f10q051515.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAP
May 14, 2015	EX-99	Argos Therapeutics Reports First Quarter 2015 Financial Results and Operational Highlights Argos Therapeutics Reports First Quarter 2015 Financial Results and Operational Highlights EXHIBIT 99.
May 14, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2015 Argos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35443 56-2110007 (State or other jurisdiction of incorporation
May 8, 2015	EX-4.5	Form of Senior Note (FACE OF SECURITY) Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE
May 8, 2015	EX-1.2	ARGOS THERAPEUTICS, INC. Common Stock (par value $0.001 per share) SALES AGREEMENT Exhibit 1.2 ARGOS THERAPEUTICS, INC. Common Stock (par value $0.001 per share) SALES AGREEMENT May 8, 2015 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Argos Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to tim
May 8, 2015	EX-4.6	Form of Subordinated Note (FACE OF SECURITY) EX-4.6 6 exh46.htm EXHIBIT 4.6 Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE
May 8, 2015	EX-4.3	ARGOS THERAPEUTICS, INC. Dated as of _______________ SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Exhibit 4.3 ARGOS THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) In
May 8, 2015	S-3	As filed with the Securities and Exchange Commission on May 8, 2015 S-3 1 fs3050415.htm FORM S-3 As filed with the Securities and Exchange Commission on May 8, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARGOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 56-2110007 (State or other jurisdiction of incorporatio
May 8, 2015	EX-4.4	ARGOS THERAPEUTICS, INC. Dated as of _______________ SUBORDINATED DEBT SECURITIES Exhibit 4.4 ARGOS THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314
May 8, 2015	EX-12.1	RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS Exhibit 12.1 RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS The following table sets forth our ratio of earnings to fixed charges and ratios of earnings to combined fixed charges and preferred stock dividends for each of the periods indicated. You should read this table in conjunction with the financial statements and notes incorp
April 13, 2015	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities 8-K 1 f8k041315.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 7, 2015 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of Inco
March 31, 2015	EX-10.27	Confidential Materials omitted and filed separately with the Confidential Materials omitted and filed separately with the Exhibit 10.27 Securities and Exchange Commission. Double asterisks denote omissions. DEVELOPMENT AGREEMENT This Development Agreement (the ?Agreement?) is entered by and between SAINT-GOBAIN PERFORMANCE PLASTICS CORPORATION, a California corporation having an office at 1199 South Chillicothe Road, Aurora, OH 44202 (?SGPPL?), and ARGOS TH
March 31, 2015	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction DC Bio Corp. Nova Scotia, Canada
March 31, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 10-K 1 f10k033115.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAPEUTIC
March 31, 2015	EX-10.29	Confidential Materials omitted and filed separately with the Confidential Materials omitted and filed separately with the Exhibit 10.29 Securities and Exchange Commission. Double asterisks denote omissions. NOVATED, AMENDED AND RESTATED LICENSE AGREEMENT by and between ARGOS THERAPEUTICS, INC., MEDINET CO., LTD. and MEDCELL CO., LTD. NOVATED, AMENDED AND RESTATED LICENSE AGREEMENT THIS NOVATED, AMENDED AND RESTATED LICENSE AGREEMENT (the ?Agreement?), effec
March 30, 2015	EX-99	Argos Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results Argos Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results EXHIBIT 99.
March 30, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2015 Argos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35443 56-2110007 (State or other jurisdiction of incorporati
March 16, 2015	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2015 Argos Therapeutics, Inc.
March 4, 2015	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2015 Argos Therapeutics, Inc.
February 20, 2015	EX-10.1	PURCHASE AND SALE AGREEMENT TKC LXXII, LLC, a North Carolina limited liability company, (the “Seller”) ARGOS THERAPEUTICS, INC., a Delaware corporation (the “Buyer”) PURCHASE AND SALE AGREEMENT Exhibit 10.1 EXECUTION COPY PURCHASE AND SALE AGREEMENT BETWEEN TKC LXXII, LLC, a North Carolina limited liability company, (the “Seller”) AND ARGOS THERAPEUTICS, INC., a Delaware corporation (the “Buyer”) PURCHASE AND SALE AGREEMENT THIS PURCHASE AND SALE AGREEMENT (this “Agreement”) is made and entered into this 16 day of February, 2015 (the “Effective Date”), by and between TKC LXXII, LLC, a No
February 20, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 16, 2015 Argos Therapeutics, Inc.
February 17, 2015	SC 13G	ARGS / Argos Therapeutics, Inc. / Cooperatieve AAC LS U.A. - SC13G Passive Investment SC13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARGOS THERAPEUTICS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 040221 103 (CUSIP Number) 31 DECEMBER 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
February 13, 2015	SC 13G	ARGS / Argos Therapeutics, Inc. / Forbion Co-Investment II Cooperatief U.A. - SC13G Passive Investment SC13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARGOS THERAPEUTICS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 040221 103 (CUSIP Number) 31 DECEMBER 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
February 12, 2015	SC 13G	ARGS / Argos Therapeutics, Inc. / Pharmstandard International S.A. - SCHEDULE 13G Passive Investment SC 13G 1 d869934dsc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ARGOS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 040221 103 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropria
February 12, 2015	EX-99.1	SCHEDULE 13G CUSIP No. 040221 103 Page 8 of 8 EX-99.1 SCHEDULE 13G CUSIP No. 040221 103 Page 8 of 8 Exhibit 99.1 JOINT FILING AGREEMENT We, the undersigned, hereby express our agreement that the attached Schedule 13G is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934. This agreement
January 9, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2015 Argos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35443 56-2110007 (State or other jurisdiction of incorporation) (Commission
January 9, 2015	EX-99	Argos Therapeutics Provides Update on Clinical Research for Investigational Fully Personalized Immunotherapy for the Treatment of HIV EXHIBIT 99.1 Argos Therapeutics Provides Update on Clinical Research for Investigational Fully Personalized Immunotherapy for the Treatment of HIV Findings from Phase 2b trial support clinical development of AGS-004 in adult eradication and pediatric studies. Company to host conference call and webcast today at 8:30 a.m. ET. DURHAM, N.C., Jan. 9, 2015 (GLOBE NEWSWIRE) - Argos Therapeutics Inc. (Na
January 7, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2015 Argos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35443 56-2110007 (State or other jurisdiction of incorporation) (Commission
January 7, 2015	EX-99	Argos Therapeutics and Saint-Gobain Announce Agreement for Production of Disposables Used in Automated Manufacturing of Fully Personalized Immunotherapies EXHIBIT 99.1 Argos Therapeutics and Saint-Gobain Announce Agreement for Production of Disposables Used in Automated Manufacturing of Fully Personalized Immunotherapies Collaboration Will Support Commercial Production of Argos Immunotherapies Based on the Arcelis(R) Technology Platform DURHAM, N.C. and AURORA, Ohio, Jan. 6, 2015 (GLOBE NEWSWIRE) - Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a
December 11, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 f8k121114.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2014 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of I
November 14, 2014	EX-10.5	Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. EX-10.5 2 exh105.htm EXHIBIT 10.5 Exhibit 10.5 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Development Agreement Argos Therapeutics, Inc. (Argos) Invetech Pty Ltd (Invetech) Development Agreement Details 4 Agreed terms 5 1. Defined terms & interpretation 5 2. Development of the Production System 11 3. Prototype
November 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35443 ARGOS THERAPEUTICS, INC. (Exact name of
November 14, 2014	EX-10.6	EX-10.6 Exhibit 10.6
November 14, 2014	EX-10.7	EX-10.7 Exhibit 10.7
November 13, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2014 Argos Therapeutics, Inc.
November 13, 2014	EX-99.1	Argos Therapeutics Reports Third Quarter 2014 Financial Results and Operational Highlights EXHIBIT 99.1 Argos Therapeutics Reports Third Quarter 2014 Financial Results and Operational Highlights Conference Call and Webcast Today, November 13th, at 4:30 p.m. ET DURHAM, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) - Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer
November 13, 2014	EX-99.2	Philippe Van Holle Joins Argos Therapeutics Board of Directors EXHIBIT 99.2 Philippe Van Holle Joins Argos Therapeutics Board of Directors DURHAM, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) - Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, today announced the
November 4, 2014	8-K	Entry into a Material Definitive Agreement 8-K 1 f8k110414.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2014 Argos Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35443 56-2110007 (State or Other Jurisdiction of I
October 31, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2014 Argos Therapeutics, Inc.
October 3, 2014	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 document.htm FORM 8-K FILING DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 3, 2014 Argos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35443 56-2110007 (State or othe
October 3, 2014	EX-99	Argos Therapeutics Announces Plans for New Manufacturing Facility in Research Triangle Park Area in Durham, North Carolina EXHIBIT 99.1 Argos Therapeutics Announces Plans for New Manufacturing Facility in Research Triangle Park Area in Durham, North Carolina State of the Art Facility Planned for Automated Production of Arcelis® Personalized Immunotherapies Project Supported by $9.5 Million in Incentives From State of North Carolina, Durham County and City of Durham DURHAM, N.C., Oct. 3, 2014 (GLOBE NEWSWIRE) - Argos T

ARGS / Argos Therapeutics, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)